Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Minerva Neurosciences (NERV) Rips 200% Higher on Positive Phase MIN-117 Trial Results
- Sanofi (SNY) Receives FDA Panel Recommendation of T2D Treatment
- FDA Approves Titan Pharma's (TTNP) Buprenorphine Implant for Treatment of Opioid Dependence
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!